...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

 No one even knows what the milesone and royalty payments will be but are critical"

as usual with commuication - always & i mean always lacking in any detail & leaving more questions than answers.

The press release gives the typical amount of detail for a license agreement in my experience --  "upfront payment of US$3.5 million, sales-based milestones and single digit royalties".  All three numbers have to be negotiated as a package.  If people wanted more up front it would mean less on the milestones and/or royalties.  Maybe we should be thankful this license agreement has nothing to do with what's currently happening/not happening with the Covid trial?

Share
New Message
Please login to post a reply